Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Program Highlights
Clinical Trials Program Targeted Antibodies
Dr. Andrew Scott (pictured) of the LICR Melbourne Centre for Clinical Sciences is using positron emission tomography (PET) to non-invasively monitor the tumor targeting and pharmacokinetics of one of LICR's targeted antibodies, which has been labeled with a trace amount of radioisotope and injected into the patient. More »
News
November 17, 2008
LICR Research Leads to US Pharmaceutical Licensing Deal
The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.
October 22, 2008
Master Switch of Lymphatic Vessel Growth Identified
In a study published this week in Nature, investigators from the Melbourne Branch of the Ludwig Institute for Cancer Research (LICR), the Institute for Molecular Bioscience (Australia) and the FIRC Institute of Molecular Oncology (Italy) report that a “genetic switch†directs the formation of new lymphatic vessels.